Experimental CAR t therapy takes aim at lupus kidney disease

NCT ID NCT06342960

First seen Nov 01, 2025 · Last updated May 04, 2026 · Updated 30 times

Summary

This early-phase study tests a new treatment called KYV-101 for people with lupus nephritis that hasn't responded to standard therapies. The treatment uses a patient's own immune cells, modified to target and destroy harmful B cells that drive the disease. The main goals are to check safety and see how the therapy behaves in the body. Only 2 adults with active lupus kidney disease are being enrolled.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUPUS NEPHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Charite- Universitätsklinikum Berlin

    Berlin, Germany

  • Fraunhofer-Institut für Translationale Medizin und Pharmakologie ITMP

    Frankfurt, Germany

  • Universitätsklinikum Carl Gustav Carus Dresden

    Dresden, Germany

  • Universitätsklinikum Düsseldorf

    Düsseldorf, Germany

  • Universitätsklinikum Erlangen

    Erlangen, Germany

  • Universitätsklinikum Hamburg-Eppendorf

    Hamburg, Germany

Conditions

Explore the condition pages connected to this study.